December 23, 2015
Article
Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.
December 22, 2015
Despite the fact that warfarin is more easily reversible, bleeding complications with the therapy are associated with longer stays in the hospital and higher mortality than dabigatran and rivaroxaban.
Research on the post-marketing surveillance of rivaroxaban found that the drug was as safe as determined from the results of the anticoagulant’s randomized controlled trial.
December 20, 2015
Patients with atrial fibrillation and renal disease who were treated with rivaroxaban (Xarelto) had less of a risk of fatal bleeding, according to a study presented at the American Heart Association Scientific Session.
Physicians are sticking with what they know when it comes to prescribing treatment for deep vein thrombosis and pulmonary embolism. Researchers found that the most common treatment remains parenteral anticoagulant with warfarin despite the arrival of a the new treatment option rivaroxaban.
December 19, 2015
Using rivaroxaban in a patients with non-valvular atrial fibrillation can reduce rates of stroke and major bleeding, according to the result of the XANTUS study.
